Karakteristik Klinis dan Profil Terapi Pasien Rawat Inap COVID-19 di Rumah Sakit Akademik Universitas Gadjah Mada Yogyakarta Periode Maret – Agustus 2020

Graciano Aristides Maturbongs; Zullies Ikawati; Nanang Munif Yasin

doi:10.22146/farmaseutik.v20i2.84987

Karakteristik Klinis dan Profil Terapi Pasien Rawat Inap COVID-19 di Rumah Sakit Akademik Universitas Gadjah Mada Yogyakarta Periode Maret – Agustus 2020

https://doi.org/10.22146/farmaseutik.v20i2.84987

Graciano Aristides Maturbongs⁽¹⁾, Zullies Ikawati^(2*), Nanang Munif Yasin⁽³⁾

(1) Fakultas Farmasi, Universitas Gadjah Mada
(2) Fakultas Farmasi, Universitas Gadjah Mada
(3) Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Coronavirus Disease (COVID-19) muncul sebagai sebuah pandemi yang menjadi masalah kesehatan global. Terapi untuk mengobati COVID-19 hingga saat ini masih berkembang dinamis. Penelitian ini bertujuan untuk memberikan gambaran karakteristik, regimen terapi, dan luaran pasien COVID-19 yang dirawat pada periode Maret – Agustus 2020 di Rumah Sakit Akademik Universitas Gadjah Mada Yogyakarta. Penelitian ini merupakan penelitian deskriptif dengan rancangan serial kasus yang dilakukan secara retrospektif. Jumlah pasien yang memenuhi kriteria inklusi adalah 24 pasien dengan 18 pasien laki-laki dan 6 pasien perempuan. Derajat keparahan pasien COVID-19 dalam penelitian ini terdiri dari tanpa gejala (25%), ringan (37,5%), sedang (29,2%), dan berat (8,3%). Batuk merupakan gejala yang paling banyak dialami oleh pasien (62,5%) diikuti demam (37,5%). Gejala lain yang juga dialami oleh pasien antara lain sesak (16,7%), pilek (12,5%), pusing (8,3%), sakit tenggorokan (8,3%), mual (8,3%), dan myalgia (11,1%). Data laboratorium menunjukkan nilai hitung leukosit dan limfosit cenderung normal namun nilai NLR cenderung meningkat. Regimen terapi yang diperoleh pasien adalah adalah antibiotik (91,7%), antivirus (4,2%), hidroksiklorokuin/klorokuin (75%), kortikosteroid (12,5%), antikoagulan (16,7%), suplemen (100%). Lama rawat inap semua pasien dalam penelitian ini adalah 9-15 hari dengan status luaran klinis pasien sembuh sebesar 20,8% dan membaik sebesar 79,2%.

Keywords

COVID-19; Luaran Klinis; Regimen Terapi

Full Text:

PDF

References

Abate, B.B., Kassie, A.M., Kassaw, M.W., Aragie, T.G., dan Masresha, S.A., 2020. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open, 10: e040129.

Ahmadi, A.-R. dan Ayazi-Nasrabadi, R., 2021. Astaxanthin protective barrier and its ability to improve the health in patients with COVID-19. Iranian Journal of Microbiology, .

Ahmadi, R., Salari, S., Sharifi, M.D., Reihani, H., Rostamiani, M.B., Behmadi, M., dkk., 2021. Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial. Food Science & Nutrition, 9: 4068–4075.

Albani, F., Sepe, L., Fusina, F., Prezioso, C., Baronio, M., Caminiti, F., dkk., 2020. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine, 27: 100562.

Boretti, A. dan Banik, B.K., 2020. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. Pharmanutrition, 12: 100190.

Boulware, D.R., Pullen, M.F., Bangdiwala, A.S., Pastick, K.A., Lofgren, S.M., Okafor, E.C., dkk., 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine, 383: 517–525.

Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, C.W., Susilo, A., dkk., 2020a. Protokol Tatalaksana COVID-19, 1st ed. Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia (IDAI), Jakarta.

Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, C.W., Susilo, A., dkk., 2020b. Pedoman Tatalaksana COVID-19 Edisi 2, 2nd ed. Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia (IDAI), Jakarta.

Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, C.W., Susilo, A., dkk., 2020c. Pedoman Tatalaksana COVID-19 Edisi 3, 3rd ed. Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia (IDAI), Jakarta.

Chen, Z., Hu, J., Zhang, Zongwei, Jiang, S., Han, S., Yan, D., dkk., 2020. 'Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial', , preprint, . Epidemiology.

Christanto, A., Listyoko, A.S., dan Putra, N.P.P., 2022. Analysis of Comorbidity and Its Association with Disease Severity and Mortality Rate in Hospitalized COVID-19 Patients. Jurnal Respirologi Indonesia, 42: 18–25.

Gautret, P., Lagier, J.-C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., dkk., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56: 105949.

Guan, W., Ni, Z., Hu, Yu, Liang, W., Ou, C., He, J., dkk., 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382: 1708–1720.

Guan, W.-J., Liang, W.-H., Zhao, Y., Liang, H.-R., Chen, Z.-S., Li, Y.-M., dkk., 2020. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. The European Respiratory Journal, 55: 2000547.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., dkk., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395: 497–506.

Isbaniah, F., Kusumowardhani, D., Sitompul, P.A., Susilo, A., Wihastuti, R., Setyawaty, V., dkk., 2020. PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISEASE (COVID-19) REVISI KE-4. Kementrian Kesehatan Republik Indonesia, Jakarta.

Jaillon, S., Berthenet, K., dan Garlanda, C., 2019. Sexual Dimorphism in Innate Immunity. Clinical Reviews in Allergy & Immunology, 56: 308–321.

Khezri, M.R., Zolbanin, N.M., Ghasemnejad-berenji, M., dan Jafari, R., 2021. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. European Journal of Pharmacology, 905: 174191.

Li, Q., Cheng, F., Xu, Q., Su, Y., Cai, X., Zeng, F., dkk., 2021. The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients. International Immunopharmacology, 95: 107531.

Libermann, T.A. dan Baltimore, D., 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Molecular and cellular biology, 10: 2327–2334.

Magdalena, Sugiri, Y.J., Tantular, R., dan Listyoko, A., 2021. Karakteristik Klinis Pasien COVID-19 di Rumah Sakit Dr.Saiful Anwar, Malang. Jurnal Respirologi Indonesia, 41: 7–10.

Marciniec, K., Beberok, A., Pęcak, P., Boryczka, S., dan Wrześniok, D., 2020. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharmacological reports : PR, 72: 1553–1561.

Oliver, M.E. dan Hinks, T.S.C., 2021. Azithromycin in viral infections. Reviews in Medical Virology, 31: e2163.

Putra Candra, A., Wiyono, W.H., Alatas, M.F., Fairuz, A., Fransiska, Bermawi, B., dkk., 2021. Covid-19 Patient Condition at Early Pandemic in Jakarta. Jurnal Respirologi Indonesia, 41: 207–213.

Retnoningrum, D., Widyastiti, N.S., dan Jaludamascena, A., 2017. HUBUNGAN ANTARA NEUTROPHIL/LYMPHOCYTE RATIO (NLR) DAN HIGH DENSITY LIPOPROTEIN (HDL) PADA SINDROM KORONER AKUT. Media Medika Muda, 2: 6.

Stellari, F.F., Sala, A., Donofrio, G., Ruscitti, F., Caruso, P., Topini, T.M., dkk., 2014. Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study. Pharmacology research & perspectives, 2: e00058.

Takahashi, T., Ellingson, M.K., Wong, P., Israelow, B., Lucas, C., Klein, J., dkk., 2020. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature, 588: 315–320.

Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., dkk., 2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, m1849.

The RECOVERY Collaborative Group, 2021. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 384: 693–704.

World Health Organization, 2020. 'WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020', . URL: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (diakses tanggal 8/6/2020).

Yacouba, A., Olowo-okere, A., dan Yunusa, I., 2021. Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Annals of Clinical Microbiology and Antimicrobials, 20: 37.

Yang, A.-P., Liu, J., Tao, W., dan Li, H., 2020. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. International Immunopharmacology, 84: 106504.

DOI: https://doi.org/10.22146/farmaseutik.v20i2.84987